Transforming growth factor beta (TGF-ß), mesenchymal-epithelial transition (MET) and breast cancer metastasis
Journal of OncoPathology, vol.2, no.4, pp.77-89, 2014 (ESCI, Scopus)
- Publication Type: Article / Review
- Volume: 2 Issue: 4
- Publication Date: 2014
- Doi Number: 10.13032/tjop.2052-5931.100112
- Journal Name: Journal of OncoPathology
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier
- Page Numbers: pp.77-89
- Keywords: Breast cancer, Mesenchymal-epithelial transition (MET), Mesenchymal-epithelial transition factor (c-MET), Metastasis, Transforming growth factor beta (TGF-ß), Treatment
- Dokuz Eylül University Affiliated: Yes
Abstract
© 2014 Optimal Clinical (Doctors. MD).Genetic and microenviromental factors model the tissue architecture. The advance of gene expression profiling and individual tumor characterizing analysis have enabled to identify the clinical significance of transforming growth factor beta (TGF-ß), epithelial-mesenchymal transition (EMT), and mesenchymal-epithelial transition (MET) signaling pathways for metastatic process. TGF-ß, a potent multifunctional (both physiologic and pathophysiologic) regulatory polypeptide, has been extensively studied in relation to malignancy. According to alterations in the composition of surrounding extracellular matrix (ECM), normal and cancer cells respond differently to TGF-ß/TGF-ß signaling pathways. The progressive research in understanding the mechanisms controlling epithelial plasticity (EMTMET) in the mammary gland can enable to identify targets for therapy and biomarkers for prognosis and prediction of treatment outcome for breast cancer patients. Therapeutic targets for TGF-ß and MET signaling pathways are in early phase clinical trials in several tumor types including mammary tumors. The review includes recent advances in these paradox pathways and their clinical implications for breast cancer.